171 related articles for article (PubMed ID: 7888070)
1. CD30, Th2 cytokines and HIV infection: a complex and fascinating link.
Del Prete G; Maggi E; Pizzolo G; Romagnani S
Immunol Today; 1995 Feb; 16(2):76-80. PubMed ID: 7888070
[TBL] [Abstract][Full Text] [Related]
2. CD30 and type 2 T helper (Th2) responses.
Romagnani S; Del Prete G; Maggi E; Chilosi M; Caligaris-Cappio F; Pizzolo G
J Leukoc Biol; 1995 May; 57(5):726-30. PubMed ID: 7759952
[TBL] [Abstract][Full Text] [Related]
3. Role for CD30 antigen in human T helper 2-type responses.
Romagnani S
Ciba Found Symp; 1995; 195():55-62; discussion 62-7. PubMed ID: 8724830
[TBL] [Abstract][Full Text] [Related]
4. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection.
Manetti R; Annunziato F; Biagiotti R; Giudizi MG; Piccinni MP; Giannarini L; Sampognaro S; Parronchi P; Vinante F; Pizzolo G; Maggi E; Romagnani S
J Exp Med; 1994 Dec; 180(6):2407-11. PubMed ID: 7964515
[TBL] [Abstract][Full Text] [Related]
5. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition.
Chilosi M; Facchetti F; Notarangelo LD; Romagnani S; Del Prete G; Almerigogna F; De Carli M; Pizzolo G
Eur J Immunol; 1996 Feb; 26(2):329-34. PubMed ID: 8617299
[TBL] [Abstract][Full Text] [Related]
6. Is CD30 (Ki-1) immunostaining in cutaneous eruptions useful as a marker of Th1 to Th2 cytokine switching and/or as a marker of advanced HIV-1 disease?
Smith KJ; Barrett TL; Neafie R; Tomaszewski MM; Yeager J; Nelson A; Wagner KF; Skelton HG
Br J Dermatol; 1998 May; 138(5):774-9. PubMed ID: 9666821
[TBL] [Abstract][Full Text] [Related]
7. Allergen-induced CD30 expression on T cells of atopic asthmatics.
Leonard C; Tormey V; Faul J; Burke CM; Poulter LW
Clin Exp Allergy; 1997 Jul; 27(7):780-6. PubMed ID: 9249270
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells.
Heuser C; Diehl V; Abken H; Hombach A
Int J Cancer; 2003 Sep; 106(4):545-552. PubMed ID: 12845650
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of CD26 as a Th1-like and CD30 as a potential Th2-like operational marker in leprosy.
Seitzer U; Scheel-Toellner D; Hahn M; Heinemann G; Mattern T; Flad HD; Gerdes J
Adv Exp Med Biol; 1997; 421():217-21. PubMed ID: 9330700
[TBL] [Abstract][Full Text] [Related]
10. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells.
D'Elios MM; Romagnani P; Scaletti C; Annunziato F; Manghetti M; Mavilia C; Parronchi P; Pupilli C; Pizzolo G; Maggi E; Del Prete GF; Romagnani S
J Leukoc Biol; 1997 May; 61(5):539-44. PubMed ID: 9129201
[TBL] [Abstract][Full Text] [Related]
11. Sequential development of Hodgkin's disease and CD30+ diffuse large B-cell lymphoma in a patient with MALT-type lymphoma: evidence of different clonal origin of single microdissected Reed-Sternberg cells.
Parrens M; Vergier B; Fitoussi O; Lahet C; Belleannee G; Marit G; Dubus P; de Mascarel A; Delfau-Larue MH; Merlio JP
Am J Surg Pathol; 2002 Dec; 26(12):1634-42. PubMed ID: 12459631
[TBL] [Abstract][Full Text] [Related]
12. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
13. CD30 expression does not discriminate between human Th1- and Th2-type T cells.
Hamann D; Hilkens CM; Grogan JL; Lens SM; Kapsenberg ML; Yazdanbakhsh M; van Lier RA
J Immunol; 1996 Feb; 156(4):1387-91. PubMed ID: 8568238
[TBL] [Abstract][Full Text] [Related]
14. Crosslinking of CD30 on activated human Th clones enhances their cytokine production and downregulates the CD30 expression.
Bengtsson A; Scheynius A; Avila-Cariño J
Scand J Immunol; 2000 Dec; 52(6):595-601. PubMed ID: 11119266
[TBL] [Abstract][Full Text] [Related]
15. CD30-mediated signaling promotes the development of human T helper type 2-like T cells.
Del Prete G; De Carli M; D'Elios MM; Daniel KC; Almerigogna F; Alderson M; Smith CA; Thomas E; Romagnani S
J Exp Med; 1995 Dec; 182(6):1655-61. PubMed ID: 7500010
[TBL] [Abstract][Full Text] [Related]
16. HIV can induce a TH1 to TH0 shift, and preferentially replicates in CD4+ T-cell clones producing TH2-type cytokines.
Romagnani S; Maggi E; Del Prete G
Res Immunol; 1994; 145(8-9):611-7; discussion 617-8. PubMed ID: 7754209
[No Abstract] [Full Text] [Related]
17. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).
Horn-Lohrens O; Tiemann M; Lange H; Kobarg J; Hafner M; Hansen H; Sterry W; Parwaresch RM; Lemke H
Int J Cancer; 1995 Feb; 60(4):539-44. PubMed ID: 7530238
[TBL] [Abstract][Full Text] [Related]
18. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
19. Activation of HIV expression by CD30 triggering in CD4+ T cells from HIV-infected individuals.
Maggi E; Annunziato F; Manetti R; Biagiotti R; Giudizi MG; Ravina A; Almerigogna F; Boiani N; Alderson M; Romagnani S
Immunity; 1995 Aug; 3(2):251-5. PubMed ID: 7648397
[TBL] [Abstract][Full Text] [Related]
20. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice.
Amakawa R; Hakem A; Kundig TM; Matsuyama T; Simard JJ; Timms E; Wakeham A; Mittruecker HW; Griesser H; Takimoto H; Schmits R; Shahinian A; Ohashi P; Penninger JM; Mak TW
Cell; 1996 Feb; 84(4):551-62. PubMed ID: 8598042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
